UCHIGATA Yasuko    Department   School of Medicine(Tokyo Women's Medical University Adachi Medical Center), School of Medicine    Position   Professor (Fixed Term)
Article types	Original article
Language	English
Peer review	Peer reviewed
Title	Renal Function after Intravitreal Administration of Vascular Endothelial Growth Factor Inhibitors in Patients with Diabetes and Chronic Kidney Disease.
Journal	Formal name：Journal of diabetes investigation Abbreviation：J Diabetes Investig ISSN code：(2040-1124)2040-1116(Linking)
Domestic / Foregin	Foregin
Volume, Issue, Page	pp.29108104
Author and coauthor	Kameda Yusuke, Babazono Tetsuya, Uchigata Yasuko, Kitano Shigehiko
Publication date	2017/11
Summary	This study aimed to determine whether intravitreal administration of vascular endothelial growth factor inhibitors is associated with deterioration of renal function, as seen with systemic administration, in patients with diabetes and chronic kidney disease. Estimated glomerular filtration rates before and after 160 intravitreal injections of vascular endothelial growth factor inhibitors (aflibercept, bevacizumab, or ranibizumab) were compared in 69 patients with diabetes and with a baseline estimated glomerular filtration rate <60 mL/min/1.73 m2 . We also determined the incidence of acute kidney injury. The data showed no significant difference in the estimated glomerular filtration rate before and after vascular endothelial growth factor inhibitor administration in all patients and in patient subgroups based on each inhibitor. Furthermore, no episodes of acute kidney injury occurred. In conclusion, intravitreal administration of vascular endothelial growth factor inhibitors is unlikely to be associated with a deterioration of renal function in patients with diabetes and chronic kidney disease. This article is protected by copyright. All rights reserved.
DOI	10.1111/jdi.12771
PMID	29108104